+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Company Analysis: Gilead

  • ID: 5357331
  • Company Profile
  • January 2021
  • 67 pages
  • Datamonitor Healthcare
The publisher explores Gilead’s prescription pharmaceutical performance and outlook over 2019-29.

Snapshot
  • Overview - Gilead’s sales will remain broadly stable over the medium term due to its strong HIV franchise, but will decline later in the forecast period due to patent expirations of key therapy backbones.
  • Key themes - [1] Stability in HIV is highly dependent on Biktarvy maintaining momentum after its initial launch period, as Gilead already has 80% market share in antiretroviral-treated patients [2] Business development efforts will continue after the Galapagos R&D transaction, with the recent acquisition of Forty Seven for $4.9bn [3] Gilead’s repeated write-offs of IPR&D intangible assets acquired in connection with the $11.9bn acquisition of Kite Pharma, combined with slowing revenue growth for Yescarta, likely implies a lower market opportunity for CAR-T therapy than initially believed.
Model updates (3 November 2020)
  • Veklury forecast adjusted lower due to Gilead commentary
  • Biktarvy forecast adjusted higher due to continued share gains
  • Jyseleca forecast adjusted lower after CRL in the US and disappointing data from Phase III program in ulcerative colitis at the 100mg dose.
Model updates (31 July 2020)
  • Veklury forecast added
  • Descovy forecast adjusted lower due to COVID-19 impact on PrEP market
  • Genvoya forecast adjusted lower due to patients switching to Biktarvy
  • Truvada forecast adjusted lower due to patients switching to Descovy
  • Yescarta forecast adjusted higher due to strong performance in Europe
  • KTE-X19 name changed to Tecartus.
Model updates (1 June 2020)
  • Biktarvy forecast adjusted higher due to continued share gains
  • Descovy forecast adjusted higher due to market share gains in PrEP
  • Truvada forecast adjusted lower due to share loss in PrEP.
Model updates (5 March 2020)
  • Descovy forecast adjusted higher due to PrEP uptake in the US
  • Truvada forecast adjusted lower due to timing of generic competition
  • Biktarvy forecast adjusted higher due to continued share gains
  • Yescarta forecast adjusted lower due to plateauing growth
  • KTE-X19 forecast added.
Note: Product cover images may vary from those shown
Company Background
  • Company Overview
  • Key Metrics
  • SWOT Analysis
  • Key Drug & Company Information
  • Company Comparison
Recent Earnings Review
  • Earnings Overview
  • Pharma Insights Analysis
Company Forecast
  • Prescription Pharmaceuticals Sales Outlook
  • Branded Drug Outlook
  • Launch Profile Outlook
  • Therapy Area Outlook
  • Regional Sales Outlook
  • Lifecycle Analysis
Company Profile
  • Marketed & Pipeline Drugs
  • Recent Events & Analyst Opinions
  • Upcoming Catalysts
  • Recent Insights
Clinical Trial Overview
  • Clinical Trial Snapshot
  • Clinical Trials by Country
  • Clinical Trials by Status and Phase
  • Clinical Trials by Drug
Note: Product cover images may vary from those shown
Adroll
adroll